Popescu, N. C., King, C. R. & Kraus, M. H. Localization of the human erbB-2 gene on regular and rearranged chromosomes 17 to bands q12-21.32. Genomics 4, 362–366 (1989).
Citri, A. & Yarden, Y. EGF-ERBB signalling: in direction of the programs degree. Nat. Rev. Mol. Cell Biol. 7, 505–516 (2006).
Gutierrez, C. & Schiff, R. HER2: biology, detection, and scientific implications. Arch. Pathol. Lab. Med. 135, 55–62 (2011).
Oh, D. Y. & Bang, Y. J. HER2-targeted therapies — a job past breast most cancers. Nat. Rev. Clin. Oncol. 17, 33–48 (2020).
Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal most cancers (MOUNTAINEER): a multicentre, open-label, part 2 research. Lancet Oncol. 24, 496–508 (2023).
FDA. FDA grants accelerated approval to tucatinib with trastuzumab for colorectal most cancers. https://www.fda.gov/medicine/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer#:~:Textual content=FDApercent20grantspercent20acceleratedpercent20approvalpercent20topercent20tucatinibpercent20withpercent20trastuzumabpercent20forpercent20colorectalpercent20cancer,-Share&Textual content=Onpercent20Januarypercent2019percent2Cpercent202023percent2Cpercent20the,(Tukysapercent2Cpercent20Seagenpercent20Inc (2023).
FDA. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive stable tumors. https://www.fda.gov/medicine/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2 (2024).
Bang, Y. J. et al. Trastuzumab together with chemotherapy versus chemotherapy alone for remedy of HER2-positive superior gastric or gastro-oesophageal junction most cancers (ToGA): a part 3, open-label, randomised managed trial. Lancet 376, 687–697 (2010).
Jorgensen, J. T. & Hersom, M. HER2 as a prognostic marker in gastric most cancers — a scientific evaluation of knowledge from the literature. J. Most cancers 3, 137–144 (2012).
Uchôa, B. C. D. M. et al. HER2-low and gastric most cancers: a prognostic biomarker? J. Clin. Oncol. https://doi.org/10.1200/JCO.2021.39.15_suppl.e16086 (2021).
Riudavets, M., Sullivan, I., Abdayem, P. & Planchard, D. Focusing on HER2 in non-small-cell lung most cancers (NSCLC): a glimpse of hope? An up to date evaluation on therapeutic methods in NSCLC harbouring HER2 alterations. ESMO Open 6, 100260 (2021).
Yoshizawa, A. et al. HER2 standing in lung adenocarcinoma: a comparability of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. Lung Most cancers 85, 373–378 (2014).
Connell, C. M. & Doherty, G. J. Activating HER2 mutations as rising targets in a number of stable cancers. ESMO Open 2, e000279 (2017).
Cocco, E., Lopez, S., Santin, A. D. & Scaltriti, M. Prevalence and position of HER2 mutations in most cancers. Pharmacol. Ther. 199, 188–196 (2019).
Chmielecki, J. et al. Oncogenic alterations in ERBB2/HER2 signify potential therapeutic targets throughout tumors from numerous anatomic websites of origin. Oncologist 20, 7–12 (2015).
Li, B. T. et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung most cancers. N. Engl. J. Med. 386, 241–251 (2022).
Goto, Okay. et al. Trastuzumab deruxtecan in sufferers with HER2-mutant metastatic non-small-cell lung most cancers: main outcomes from the randomized, part II DESTINY-lung02 trial. J. Clin. Oncol. 41, 4852–4863 (2023).
FDA. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung most cancers. https://www.fda.gov/medicine/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung (2022).
Zabransky, D. J. et al. HER2 missense mutations have distinct results on oncogenic signaling and migration. Proc. Natl Acad. Sci. USA 112, E6205–E6214 (2015).
Shigematsu, H. et al. Somatic mutations of the HER2 kinase area in lung adenocarcinomas. Most cancers Res. 65, 1642–1646 (2005).
Greulich, H. et al. Practical evaluation of receptor tyrosine kinase mutations in lung most cancers identifies oncogenic extracellular area mutations of ERBB2. Proc. Natl Acad. Sci. USA 109, 14476–14481 (2012).
Meric-Bernstam, F. et al. Advances in HER2-targeted remedy: novel brokers and alternatives past breast and gastric most cancers. Clin. Most cancers Res. 25, 2033–2041 (2019).
Xia, X., Gong, C., Zhang, Y. & Xiong, H. The historical past and improvement of HER2 inhibitors. Prescribed drugs 16, 1450 (2023).
Banerji, U. et al. Trastuzumab duocarmazine in regionally superior and metastatic stable tumours and HER2-expressing breast most cancers: a part 1 dose-escalation and dose-expansion research. Lancet Oncol. 20, 1124–1135 (2019).
Xu, Y. et al. Part I research of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in sufferers with HER2-positive superior stable tumors. Gastric Most cancers 24, 913–925 (2021).
Weisser, N. E. et al. An anti-HER2 biparatopic antibody that induces distinctive HER2 clustering and complement-dependent cytotoxicity. Nat. Commun. 14, 1394 (2023).
Xu, J. et al. KN026 (anti-HER2 bispecific antibody) in sufferers with beforehand handled, superior HER2-expressing gastric or gastroesophageal junction most cancers. Eur. J. Most cancers 178, 1–12 (2023).
Again, J. et al. GBR1302: impact of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers. J. Clin. Oncol. https://doi.org/10.1200/JCO.2018.36.15_suppl.120 (2018).
Rudnik, M. et al. Mixed investigation of anti-tumor efficacy and liver security of bispecific T cell engagers in immune-competent high-throughput co-culturing platform. Most cancers Res. 83, 2747 (2023).
Kim, Okay. M. et al. Human epidermal progress issue receptor 2 testing in gastric most cancers: suggestions of an Asia-Pacific activity drive. Asia Pac. J. Clin. Oncol. 10, 297–307 (2014).
Valtorta, E. et al. Evaluation of a HER2 scoring system for colorectal most cancers: outcomes from a validation research. Mod. Pathol. 28, 1481–1491 (2015).
Buza, N., English, D. P., Santin, A. D. & Hui, P. Towards normal HER2 testing of endometrial serous carcinoma: 4-year expertise at a big educational heart and suggestions for scientific apply. Mod. Pathol. 26, 1605–1612 (2013).
Lamarca, A. et al. The HER3 pathway as a possible goal for inhibition in sufferers with biliary tract cancers. PLoS ONE 13, e0206007 (2018).
Meric-Bernstam, F. et al. Efficacy and security of trastuzumab deruxtecan in sufferers with HER2-expressing stable tumors: main outcomes from the DESTINY-PanTumor02 part II trial. J. Clin. Oncol. 42, 47–58 (2024).
DiPeri, T. P. et al. Discordance of HER2 expression and/or amplification on repeat testing. Mol. Most cancers Ther. 22, 976–984 (2023).
Hashimoto, T. et al. A complete appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal most cancers. Br. J. Most cancers 129, 1176–1183 (2023).
Zehir, A. et al. Mutational panorama of metastatic most cancers revealed from potential scientific sequencing of 10,000 sufferers. Nat. Med. 23, 703–713 (2017).
Hyman, D. M. et al. HER kinase inhibition in sufferers with HER2- and HER3-mutant cancers. Nature 554, 189–194 (2018).
Wu, L. et al. Panorama of somatic alterations in large-scale stable tumors from an Asian inhabitants. Nat. Commun. 13, 4264 (2022).
Bontoux, C. et al. Deciphering the affect of HER2 alterations on non-small-cell lung most cancers: from organic mechanisms to therapeutic approaches. J. Pers. Med. 12, 1651 (2022).
Vaghi, C. et al. The predictive position of ERBB2 level mutations in metastatic colorectal most cancers: a scientific evaluation. Most cancers Deal with. Rev. 112, 102488 (2023).
Li, B. T. et al. Trastuzumab deruxtecan in sufferers with stable tumours harbouring particular activating HER2 mutations (DESTINY-PanTumor01): a global, part 2 research. Lancet Oncol. 25, 707–719 (2024).
Modi, S. et al. Trastuzumab deruxtecan in beforehand handled HER2-low superior breast most cancers. N. Engl. J. Med. 387, 9–20 (2022).
Uzunparmak, B. et al. HER2-low expression in sufferers with superior or metastatic stable tumors. Ann. Oncol. 34, 1035–1046 (2023).
Yamaguchi, Okay. et al. Trastuzumab deruxtecan in anti-human epidermal progress issue receptor 2 treatment-naive sufferers with human epidermal progress issue receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort leads to a part II trial. J. Clin. Oncol. 41, 816–825 (2023).
Ohba, A. et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in sufferers (pts) with HER2-expressing unresectable or recurrent biliary tract most cancers (BTC): an investigator-initiated multicenter part 2 research (HERB trial). J. Clin. Oncol. https://doi.org/10.1200/JCO.2022.40.16_suppl.4006 (2022).
Nishikawa, T. et al. Trastuzumab deruxtecan for human epidermal progress issue receptor 2-expressing superior or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial. J. Clin. Oncol. 41, 2789–2799 (2023).
Yoshino, T. et al. Last outcomes of DESTINY-CRC01 investigating trastuzumab deruxtecan in sufferers with HER2-expressing metastatic colorectal most cancers. Nat. Commun. 14, 3332 (2023).
Meric-Bernstam, F. et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal most cancers (MyPathway): an up to date report from a multicentre, open-label, part 2a, a number of basket research. Lancet Oncol. 20, 518–530 (2019).
Sartore-Bianchi, A. et al. Twin-targeted remedy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal most cancers (HERACLES): a proof-of-concept, multicentre, open-label, part 2 trial. Lancet Oncol. 17, 738–746 (2016).
Leyland-Jones, B. Trastuzumab: hopes and realities. Lancet Oncol. 3, 137–144 (2002).
Nahta, R. & Esteva, F. J. Trastuzumab: triumphs and tribulations. Oncogene 26, 3637–3643 (2007).
Fader, A. N. et al. Randomized part II trial of carboplatin–paclitaxel versus carboplatin–paclitaxel–trastuzumab in uterine serous carcinomas that overexpress human epidermal progress issue receptor 2/neu. J. Clin. Oncol. 36, 2044–2051 (2018).
Fader, A. N. et al. Randomized part II trial of carboplatin-paclitaxel in contrast with carboplatin-paclitaxel-trastuzumab in superior (stage III–IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): up to date general survival evaluation. Clin. Most cancers Res. 26, 3928–3935 (2020).
Takahashi, H. et al. Part II trial of trastuzumab and docetaxel in sufferers with human epidermal progress issue receptor 2-positive salivary duct carcinoma. J. Clin. Oncol. 37, 125–134 (2019).
Nam, A. R. et al. Therapeutic implication of HER2 in superior biliary tract most cancers. Oncotarget 7, 58007–58021 (2016).
Lee, C. Okay. et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract most cancers refractory to gemcitabine and cisplatin: a multi-institutional part 2 trial of the Korean Most cancers Examine Group (KCSG-HB19-14). Lancet Gastroenterol. Hepatol. 8, 56–65 (2023).
Kim, M. et al. Part II research of a trastuzumab biosimilar together with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18. ESMO Open 8, 101588 (2023).
Barthelemy, P., Leblanc, J., Goldbarg, V., Wendling, F. & Kurtz, J. E. Pertuzumab: improvement past breast most cancers. Anticancer Res. 34, 1483–1491 (2014).
Oh, D. Y. & Bang, Y. J. Pertuzumab in gastrointestinal most cancers. Professional Opin. Biol. Ther. 16, 243–253 (2016).
Tabernero, J. et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction most cancers (JACOB): remaining evaluation of a double-blind, randomised, placebo-controlled part 3 research. Lancet Oncol. 19, 1372–1384 (2018).
Tabernero, J. et al. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction most cancers: end-of-study evaluation of the JACOB part III randomized scientific trial. Gastric Most cancers 26, 123–131 (2023).
Javle, M. et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract most cancers (MyPathway): a multicentre, open-label, part 2a, a number of basket research. Lancet Oncol. 22, 1290–1300 (2021).
Sweeney, C. J. et al. MyPathway human epidermal progress issue receptor 2 basket research: pertuzumab + trastuzumab remedy of a tissue-agnostic cohort of sufferers with human epidermal progress issue receptor 2-altered superior stable tumors. J. Clin. Oncol. 42, 258–265 (2024).
Markham, A. Margetuximab: first approval. Medicine 81, 599–604 (2021).
Bang, Y. J. et al. First-in-human part 1 research of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in sufferers with HER2-positive superior stable tumors. Ann. Oncol. 28, 855–861 (2017).
Catenacci, D. V. T. et al. Margetuximab plus pembrolizumab in sufferers with beforehand handled, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, part 1b-2 trial. Lancet Oncol. 21, 1066–1076 (2020).
Catenacci, D. V. T. et al. Margetuximab with retifanlimab as first-line remedy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. ESMO Open 7, 100563 (2022).
Voigtlaender, M., Schneider-Merck, T. & Trepel, M. Lapatinib. Latest Outcomes Most cancers Res. 211, 19–44 (2018).
Satoh, T. et al. Lapatinib plus paclitaxel versus paclitaxel alone within the second-line remedy of HER2-amplified superior gastric most cancers in Asian populations: TyTAN — a randomized, part III research. J. Clin. Oncol. 32, 2039–2049 (2014).
Hecht, J. R. et al. Lapatinib together with capecitabine plus oxaliplatin in human epidermal progress issue receptor 2-positive superior or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC — a randomized part III trial. J. Clin. Oncol. 34, 443–451 (2016).
Bose, R. et al. Activating HER2 mutations in HER2 gene amplification detrimental breast most cancers. Most cancers Discov. 3, 224–237 (2013).
Friedman, C. F. et al. Focusing on HER2-mutant metastatic cervical most cancers with neratinib: remaining outcomes from the part 2 SUMMIT basket trial. Gynecol. Oncol. 181, 162–169 (2024).
Harding, J. J. et al. Antitumour exercise of neratinib in sufferers with HER2-mutant superior biliary tract cancers. Nat. Commun. 14, 630 (2023).
Liu, D. et al. Pyrotinib alone or together with docetaxel in refractory HER2-positive gastric most cancers: a dose-escalation part I research. Most cancers Med. 12, 10704–10714 (2023).
Chang, J. et al. Twin HER2 focused remedy with pyrotinib and trastuzumab in refractory HER2 constructive metastatic colorectal most cancers: a consequence from HER2-FUSCC-G research. Clin. Colorectal Most cancers 21, 347–353 (2022).
Zhou, C. et al. Pyrotinib in HER2-mutant superior lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, part II research. J. Clin. Oncol. 38, 2753–2761 (2020).
Liu, S. M. et al. First-line pyrotinib in superior HER2-mutant non-small-cell lung most cancers: a patient-centric part 2 trial. Nat. Med. 29, 2079–2086 (2023).
Kim, T. M. et al. Part 1 research of poziotinib, an irreversible pan-HER tyrosine kinase inhibitor in sufferers with superior stable tumors. Most cancers Res. Deal with. 50, 835–842 (2018).
Kim, T. Y. et al. A part I/II research of poziotinib mixed with paclitaxel and trastuzumab in sufferers with HER2-positive superior gastric most cancers. Gastric Most cancers 22, 1206–1214 (2019).
Le, X. et al. Poziotinib in non-small-cell lung most cancers harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial. J. Clin. Oncol. 40, 710–718 (2022).
Cornelissen, R. et al. Poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: ZENITH20-4, a multicenter, multicohort, open-label, part 2 trial (cohort 4). J. Thorac. Oncol. 18, 1031–1041 (2023).
Olson, D. J. et al. Preclinical characterization of tucatinib in HER2-amplified xenograft and CNS implanted tumors. Most cancers Res. 80, 1962 (2020).
Moulder, S. L. et al. Part I research of ONT-380, a HER2 inhibitor, in sufferers with HER2(+)-advanced stable tumors, with an growth cohort in HER2(+) metastatic breast most cancers (MBC). Clin. Most cancers Res. 23, 3529–3536 (2017).
Bekaii-Saab, T. S. et al. MOUNTAINEER-03: part 3 research of tucatinib, trastuzumab, and mFOLFOX6 as first-line remedy in HER2+ metastatic colorectal most cancers — trial in progress. J. Clin. Oncol. 41, https://doi.org/10.1200/JCO.2023.41.4_suppl.TPS261 (2023).
Tehfe, M. et al. Part II dose optimization outcomes from MOUNTAINEER-02: a research of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal most cancers (GEC). Ann. Oncol. 34, S857–S858 (2023).
Reck, M. et al. SGNTUC-019: part II basket research of tucatinib and trastuzumab in beforehand handled stable tumors with HER2 alterations. Ann. Oncol. 32, S614–S615 (2021).
Nakamura, Y. et al. Tucatinib and trastuzumab for beforehand handled human epidermal progress issue receptor 2-positive metastatic biliary tract most cancers (SGNTUC-019): a part II basket research. J. Clin. Oncol. 41, 5569–5578 (2023).
Yu, E. Y., Jin, F., Ramos, J., Tan, Q. & Galsky, M. D. A part 2 basket research of tucatinib and trastuzumab in beforehand handled stable tumors with HER2 alterations: urothelial most cancers cohort J. Clin. Oncol. https://doi.org/10.1200/JCO.2023.41.6_suppl.TPS587 (2023).
Monk, B., Jin, F., Ramos, J., Tan, Q. & O’Malley, D. A part 2 basket research of tucatinib and trastuzumab in stable tumors with human epidermal progress issue receptor 2 alterations: uterine and cervical most cancers cohorts (SGNTUC-019, trial in progress). Gynecol. Oncol. 176, S165–S166 (2023).
Heymach, J. et al. A part I, open-label, dose affirmation, escalation, and growth trial of BI 1810631 as monotherapy in sufferers with superior or metastatic stable tumors with HER2 aberrations. Clin. Lung Most cancers 24, e65–e68 (2023).
Hong, M. H. et al. 1333P A world part 1b research of ORIC-114, a extremely selective, mind penetrant EGFR and HER2 inhibitor, in sufferers with superior stable tumors harboring EGFR exon 20 or HER2 alterations. Ann. Oncol. 34, S769 (2023).
Liu, J. et al. Mechanism and remedy of diarrhea related to tyrosine kinase inhibitors. Heliyon 10, e27531 (2024).
Thuss-Persistence, P. C. et al. Trastuzumab emtansine versus taxane use for beforehand handled HER2-positive regionally superior or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): a global randomised, open-label, adaptive, part 2/3 research. Lancet Oncol. 18, 640–653 (2017).
Li, B. T. et al. Ado-trastuzumab emtansine for sufferers with HER2-mutant lung cancers: outcomes from a part II basket trial. J. Clin. Oncol. 36, 2532–2537 (2018).
Peters, S. et al. Trastuzumab emtansine (T-DM1) in sufferers with beforehand handled HER2-overexpressing metastatic non-small cell lung most cancers: efficacy, security, and biomarkers. Clin. Most cancers Res. 25, 64–72 (2019).
Sartore-Bianchi, A. et al. Pertuzumab and trastuzumab emtansine in sufferers with HER2-amplified metastatic colorectal most cancers: the part II HERACLES-B trial. ESMO Open 5, e000911 (2020).
Nakada, T. et al. Novel antibody–drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg. Med. Chem. Lett. 26, 1542–1545 (2016).
Ogitani, Y., Hagihara, Okay., Oitate, M., Naito, H. & Agatsuma, T. Bystander killing impact of DS-8201a, a novel anti-human epidermal progress issue receptor 2 antibody–drug conjugate, in tumors with human epidermal progress issue receptor 2 heterogeneity. Most cancers Sci. 107, 1039–1046 (2016).
Doi, T. et al. Security, pharmacokinetics, and antitumour exercise of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in sufferers with superior breast and gastric or gastro-oesophageal tumours: a part 1 dose-escalation research. Lancet Oncol. 18, 1512–1522 (2017).
Shitara, Okay. et al. Trastuzumab deruxtecan in beforehand handled HER2-positive gastric most cancers. N. Engl. J. Med. 382, 2419–2430 (2020).
Swain, S. M. et al. Multidisciplinary scientific steerage on trastuzumab deruxtecan (T-DXd)-related interstitial lung illness/pneumonitis — concentrate on proactive monitoring, analysis, and administration. Most cancers Deal with. Rev. 106, 102378 (2022).
Errisuriz, Okay., Bazan, D. Z., Verduzco, R. Jr. & Guedez, R. Trastuzumab-induced interstitial pneumonitis. Cureus 15, e42116 (2023).
Van Cutsem, E. et al. Trastuzumab deruxtecan in sufferers within the USA and Europe with HER2-positive superior gastric or gastroesophageal junction most cancers with illness development on or after a trastuzumab-containing routine (DESTINY-Gastric02): main and up to date analyses from a single-arm, part 2 research. Lancet Oncol. 24, 744–756 (2023).
Shitara, Okay. et al. Trastuzumab deruxtecan (T-DXd) in sufferers with HER2-positive gastric most cancers (GC) or gastroesophageal junction (GEJ) adenocarcinoma who’ve progressed on or after a trastuzumab-containing routine (DESTINY-Gastric04): a randomized part 3 research. Ann. Oncol. 33, S306–S307 (2022).
Smit, E. F. et al. Trastuzumab deruxtecan in sufferers with metastatic non-small-cell lung most cancers (DESTINY-Lung01): main outcomes of the HER2-overexpressing cohorts from a single-arm, part 2 trial. Lancet Oncol. 25, 439–454 (2024).
Raghav, Okay. P. S. et al. Trastuzumab deruxtecan (T-DXd) in sufferers (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal most cancers (mCRC): main outcomes from the multicenter, randomized, part 2 DESTINY-CRC02 research. J. Clin. Oncol. https://doi.org/10.1200/JCO.2023.41.16_suppl.3501 (2023).
Elgersma, R. C. et al. Design, synthesis, and analysis of linker-duocarmycin payloads: towards number of HER2-targeting antibody–drug conjugate SYD985. Mol. Pharm. 12, 1813–1835 (2015).
Li, H. W. et al. An anti-HER2 antibody conjugated with monomethyl auristatin E is very efficient in HER2-positive human gastric most cancers. Most cancers Biol. Ther. 17, 346–354 (2016).
Peng, Z. et al. Efficacy and security of a novel anti-HER2 therapeutic antibody RC48 in sufferers with HER2-overexpressing, regionally superior or metastatic gastric or gastroesophageal junction most cancers: a single-arm part II research. Most cancers Commun (Lond.) 41, 1173–1182 (2021).
Sheng, X. et al. Open-label, multicenter, part II research of RC48-ADC, a HER2-targeting antibody–drug conjugate, in sufferers with regionally superior or metastatic urothelial carcinoma. Clin. Most cancers Res. 27, 43–51 (2021).
Barnscher, S. D., Rojas, A. H., Hamblett, Okay. J. & Escalante, N. Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell loss of life and is energetic in patient-derived xenograft fashions of gastric most cancers. Most cancers Res. 83, 2633 (2023).
Jhaveri, Okay. et al. Preliminary outcomes from a part I research utilizing the bispecific, human epidermal progress issue 2 (HER2)-targeting antibody–drug conjugate (ADC) zanidatamab zovodotin (ZW49) in stable cancers. Ann. Oncol. https://doi.org/10.1016/j.annonc.2022.07.589 (2022).
Zhang, T. et al. SHR-A1811, a novel anti-HER2 ADC with superior bystander impact, optimum DAR and favorable security profiles. Most cancers Res. 83, LB031 (2023).
Yao, H. et al. The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated superior non-breast stable tumors (STs): outcomes from the worldwide part I research. Ann. Oncol. 34, S461–S462 (2023).
Yao, H. et al. Security, efficacy, and pharmacokinetics of shr-a1811, a human epidermal progress issue receptor 2-directed antibody–drug conjugate, in human epidermal progress issue receptor 2-expressing or mutated superior stable tumors: a world part I trial. J. Clin. Oncol. https://doi.org/10.1200/JCO.23.02044 (2024).
Lin, F. et al. Part I research of ZV0203, a primary in school pertuzumab ADC, in sufferers with HER2+ superior stable tumors. Ann. Oncol. 34, S365 (2023).
Miao, Z. et al. Part 1 research of ZV0203, a primary in school pertuzumab ADC, in sufferers with HER2 constructive superior stable tumors. J. Clin. Oncol. https://doi.org/10.1200/JCO.2024.42.16_suppl.e15004 (2024).
Meric-Bernstam, F. et al. Zanidatamab, a novel bispecific antibody, for the remedy of regionally superior or metastatic HER2-expressing or HER2-amplified cancers: a part 1, dose-escalation and growth research. Lancet Oncol. 23, 1558–1570 (2022).
Harding, J. J. et al. Zanidatamab for HER2-amplified, unresectable, regionally superior or metastatic biliary tract most cancers (HERIZON-BTC-01): a multicentre, single-arm, part 2b research. Lancet Oncol. 24, 772–782 (2023).
Lamarca, A. et al. Second-line FOLFOX chemotherapy versus energetic symptom management for superior biliary tract most cancers (ABC-06): a part 3, open-label, randomised, managed trial. Lancet Oncol. 22, 690–701 (2021).
Meric-Bernstam, F. et al. Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): outcomes from a part I research. J. Clin. Oncol. https://doi.org/10.1200/JCO.2021.39.3_suppl.164 (2021).
Ku, G. et al. Part (Ph) II research of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA). Ann. Oncol. 32, S1044–S1045 (2021).
Wei, H. et al. Structural foundation of a novel heterodimeric Fc for bispecific antibody manufacturing. Oncotarget 8, 51037–51049 (2017).
Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. Bispecific antibodies: a mechanistic evaluation of the pipeline. Nat. Rev. Drug Discov. 18, 585–608 (2019).
Again, J. GBR1302-BEAT® bispecific antibody focusing on CD3 and HER2 demonstrates the next anti-tumor potential than present HER2-targeting therapies. Ann. Oncol. https://doi.org/10.1093/annonc/mdw525.04 (2016).
Wermke, M. et al. Preliminary outcomes from a part I research of GBR 1302, a bispecific antibody T-cell engager, in HER2 constructive cancers. Ann. Oncol. 29, VIII408–VIII409 (2018).
Vinay, D. S. & Kwon, B. S. 4-1BB (CD137), an inducible costimulatory receptor, as a selected goal for most cancers remedy. BMB Rep. 47, 122–129 (2014).
Hinner, M. J. et al. Tumor-localized costimulatory T-cell engagement by the 4-1BB/HER2 bispecific antibody–anticalin fusion PRS-343. Clin. Most cancers Res. 25, 5878–5889 (2019).
Ku, G. et al. A part I dose escalation research of PRS-343, a HER2/4-1BB bispecific molecule, in sufferers with HER2-positive malignancies. Ann. Oncol. https://doi.org/10.1016/j.annonc.2020.08.639 (2020).
Ku, G. et al. A part 2, multi-center, open-label research of cinrebafusp alfa (PRS-343) in sufferers with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma. Ann. Oncol. 33, S265 (2022).
Ku, G. et al. Mixture of cinrebafusp alfa with ramucirumab and paclitaxel is effectively tolerated and elicits encouraging scientific exercise in sufferers with HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma. Most cancers Res. https://doi.org/10.1158/1538-7445.AM2023-CT154 (2023).
Lee, E. et al. A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts vital anti-tumor results by way of tumor-directed T cell activation. Ann. Oncol. 32, S607–S608 (2021).
Jiang, Z., Solar, H., Yu, J., Tian, W. & Tune, Y. Focusing on CD47 for most cancers immunotherapy. J. Hematol. Oncol. 14, 180 (2021).
Zhang, B. et al. Preclinical improvement of a novel bispecific mAb-Entice fusion protein, IMM2902, focusing on each HER2 and CD47 as most cancers immunotherapy. Most cancers Res. 83, 2938 (2023).
Meng, Y. et al. Preliminary outcomes of a part I, first-in-human, dose escalation research of IMM2902 in sufferers with HER2-expressing superior stable tumors. J. Clin. Oncol. https://doi.org/10.1200/JCO.2023.41.16_suppl.e151 (2023).
Safran, H. et al. Part 1/2 research of DF1001, a novel tri-specific, NK cell engager remedy focusing on HER2, in sufferers with superior stable tumors: part 1 DF1001 monotherapy dose-escalation outcomes. J. Clin. Oncol. https://doi.org/10.1200/JCO.2023.41.16_suppl.2508 (2023).
Conilh, L., Sadilkova, L., Viricel, W. & Dumontet, C. Payload diversification: a key step within the improvement of antibody–drug conjugates. J. Hematol. Oncol. 16, 3 (2023).
Li, B. T. et al. A part 1/2 research of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in sufferers with superior HER2-expressing stable tumors. J. Clin. Oncol. https://doi.org/10.1200/JCO.2023.41.16_suppl.2538 (2023).
Metz, H. et al. SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist. J. Clin. Oncol. https://doi.org/10.1200/JCO.2020.38.15_suppl.311 (2020).
Klempner, S. J. et al. Interim outcomes of a part I/Ib research of SBT6050 monotherapy and pembrolizumab mixture in sufferers with superior HER2-expressing or amplified stable tumors. Ann. Oncol. https://doi.org/10.1016/j.annonc.2021.08.491 (2021).
Albelda, S. M. CAR T cell remedy for sufferers with stable tumours: key classes to study and unlearn. Nat. Rev. Clin. Oncol. 21, 47–66 (2024).
Morgan, R. A. et al. Case report of a critical adversarial occasion following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).
Sen, M. et al. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells towards HER2/neu+ tumors. J. Hematother. Stem Cell Res. 10, 247–260 (2001).
Vaishampayan, U. N. et al. Part II trial of pembrolizumab and anti-CD3 × anti-HER2 bispecific antibody-armed activated T cells in metastatic castration-resistant prostate most cancers. Clin. Most cancers Res. 29, 122–133 (2023).
Gabrusiewicz, Okay. et al. CT-0508, a novel CAR macrophage product directed towards HER2, promotes a proinflammatory tumor microenvironment. Most cancers Immunol. Res. 8, B65 (2020).
Reiss, Okay. et al. A part 1, first-in-human (FIH) scientific trial of the anti-HER2 CAR macrophage CT-0508 in individuals with HER2 overexpressing stable tumors. J. Immunother. Most cancers https://doi.org/10.1136/jitc-2022-SITC2022.0634 (2022).
Wang, L. et al. Affected person-derived TAC01-HER2 TAC T cells produced in Cocoon® Platform is very purposeful in fashions of stable tumors. Most cancers Res. https://doi.org/10.1158/1538-7445.AM2023-3188 (2023).
Schlechter, B. L. et al. A part I/II trial investigating security and efficacy of autologous TAC01-HER2 in relapsed or refractory stable tumors. J. Clin. Oncol. https://doi.org/10.1200/JCO.2024.42.3_suppl.747 (2024).
Lin, M. J. et al. Most cancers vaccines: the subsequent immunotherapy frontier. Nat. Most cancers 3, 911–926 (2022).
Ede, N. J. et al. Improvement of the B cell most cancers vaccine HER-vaxx for the remedy of her-2 expressing cancers. Entrance Oncol. 12, 939356 (2022).
Wiedermann, U. et al. Medical and immunologic responses to a B-cell epitope vaccine in sufferers with HER2/neu-overexpressing superior gastric most cancers — outcomes from part Ib trial IMU.ACS.001. Clin. Most cancers Res. 27, 3649–3660 (2021).
Maglakelidze, M. et al. HERIZON: a part 2 research of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus normal of care chemotherapy in sufferers with HER2-overexpressing metastatic or superior gastric/GEJ adenocarcinoma — general survival evaluation. J. Clin. Oncol. https://doi.org/10.1200/JCO.2023.41.4_suppl.289 (2023).
Bekes, M., Langley, D. R. & Crews, C. M. PROTAC focused protein degraders: the previous is prologue. Nat. Rev. Drug Discov. 21, 181–200 (2022).
Hu, M. et al. Discovery of potent and selective HER2 PROTAC degrader primarily based tucatinib with improved efficacy towards HER2 constructive cancers. Eur. J. Med. Chem. 244, 114775 (2022).
Maneiro, M. A. et al. Antibody–PROTAC conjugates allow HER2-dependent focused protein degradation of BRD4. ACS Chem. Biol. 15, 1306–1312 (2020).
Le Joncour, V. et al. A novel anti-HER2 antibody–drug conjugate XMT-1522 for HER2-positive breast and gastric cancers proof against trastuzumab emtansine. Mol. Most cancers Ther. 18, 1721–1730 (2019).
Skidmore, L. et al. ARX788, a site-specific anti-HER2 antibody–drug conjugate, demonstrates potent and selective exercise in HER2-low and T-DM1-resistant breast and gastric cancers. Mol. Most cancers Ther. 19, 1833–1843 (2020).
Pietrantonio, F. et al. HER2 loss in HER2-positive gastric or gastroesophageal most cancers after trastuzumab remedy: implication for additional scientific analysis. Int. J. Most cancers 139, 2859–2864 (2016).
Saeki, H. et al. Re-evaluation of HER2 standing in sufferers with HER2-positive superior or recurrent gastric most cancers refractory to trastuzumab (KSCC1604). Eur. J. Most cancers 105, 41–49 (2018).
Search engine optimization, S. et al. Lack of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric most cancers sufferers: outcomes of the GASTric most cancers HER2 reassessment research 3 (GASTHER3). Gastric Most cancers 22, 527–535 (2019).
Yu, M., Liang, Y., Li, L., Zhao, L. & Kong, F. Analysis progress of antibody–drug conjugates remedy for HER2-low expressing gastric most cancers. Transl. Oncol. 29, 101624 (2023).
Hong, J. et al. Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma. Most cancers Res. 72, 4504–4514 (2012).
Shi, M. et al. Catecholamine-induced beta2-adrenergic receptor activation mediates desensitization of gastric most cancers cells to trastuzumab by upregulating MUC4 expression. J. Immunol. 190, 5600–5608 (2013).
Duarte, H. O. et al. ST6Gal1 targets the ectodomain of ErbB2 in a site-specific method and regulates gastric most cancers cell sensitivity to trastuzumab. Oncogene 40, 3719–3733 (2021).
Wang, D. S. et al. Liquid biopsies to trace trastuzumab resistance in metastatic HER2-positive gastric most cancers. Intestine 68, 1152–1161 (2019).
Ohba, A. et al. Circulating tumor DNA (ctDNA) analyses in sufferers with HER2-positive biliary tract most cancers (BTC) handled with trastuzumab deruxtecan (T-DXd): exploratory outcomes from the HERB trial. J. Clin. Oncol. https://doi.org/10.1200/JCO.2023.41.16_suppl.4097 (2023).
Siravegna, G. et al. Radiologic and genomic evolution of particular person metastases throughout HER2 blockade in colorectal most cancers. Most cancers Cell 34, 148–162.e7 (2018).
Ding, X. et al. Systematic molecular profiling of inhibitor response to the scientific missense mutations of ErbB household kinases in human gastric most cancers. J. Mol. Graph. Mannequin. 96, 107526 (2020).
Ma, C., Wang, X., Guo, J., Yang, B. & Li, Y. Challenges and way forward for HER2-positive gastric most cancers remedy. Entrance. Oncol. 13, 1080990 (2023).
Kaito, A. et al. HER2 heterogeneity is a poor prognosticator for HER2-positive gastric most cancers. World J. Clin. Circumstances 7, 1964–1977 (2019).
Bang, Okay. et al. Affiliation between HER2 heterogeneity and scientific outcomes of HER2-positive gastric most cancers sufferers handled with trastuzumab. Gastric Most cancers 25, 794–803 (2022).
Haffner, I. et al. HER2 expression, take a look at deviations, and their affect on survival in metastatic gastric most cancers: outcomes from the potential multicenter VARIANZ research. J. Clin. Oncol. 39, 1468–1478 (2021).
Suzuki, M. et al. Visualization of intratumor pharmacokinetics of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2 heterogeneous mannequin utilizing phosphor-integrated dots imaging evaluation. Clin. Most cancers Res. 27, 3970–3979 (2021).
Eto, Okay. et al. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric most cancers cells to trastuzumab. Ann. Surg. Oncol. 21, 343–350 (2014).
Tang, L. et al. NES1/KLK10 promotes trastuzumab resistance by way of activation of PI3K/AKT signaling pathway in gastric most cancers. J. Cell. Biochem. 119, 6398–6407 (2018).
Deguchi, Y. et al. PTEN loss is related to a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma. Gastric Most cancers 20, 416–427 (2017).
Mezynski, M. J. et al. Focusing on the PI3K and MAPK pathways to enhance response to HER2-targeted therapies in HER2-positive gastric most cancers. J. Transl. Med. 19, 184 (2021).
Ning, G. et al. A novel remedy technique for lapatinib resistance in a subset of HER2-amplified gastric most cancers. BMC Most cancers 21, 923 (2021).
Hong, Y. S. et al. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma fashions. PLoS ONE 9, e109440 (2014).
Jin, M. H. et al. Resistance mechanism towards trastuzumab in HER2-positive most cancers cells and its negation by src inhibition. Mol. Most cancers Ther. 16, 1145–1154 (2017).
Su, B. et al. Apatinib reveals synergistic impact with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric most cancers by way of stem cell issue/c-kit signaling and its downstream pathways. Gastric Most cancers 24, 352–367 (2021).
Liu, J. et al. A brand new mechanism of trastuzumab resistance in gastric most cancers: MACC1 promotes the Warburg impact by way of activation of the PI3K/AKT signaling pathway. J. Hematol. Oncol. 9, 76 (2016).
Sanchez-Vega, F. et al. EGFR and MET amplifications decide response to HER2 inhibition in ERBB2-amplified esophagogastric most cancers. Most cancers Discov. 9, 199–209 (2019).
Chen, C. T. et al. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric most cancers cells. Mol. Most cancers Ther. 11, 660–669 (2012).
Lee, Y. Y. et al. Phosphoproteomic evaluation identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant most cancers cell line. Exp. Mol. Med. 45, e64 (2013).
Park, J. et al. FOXO1 suppression is a determinant of acquired lapatinib-resistance in HER2-positive gastric most cancers cells by way of MET upregulation. Most cancers Res. Deal with. 50, 239–254 (2018).
Yoshioka, T. et al. Acquired resistance mechanisms to afatinib in HER2-amplified gastric most cancers cells. Most cancers Sci. 110, 2549–2557 (2019).
Liao, H. et al. The importance of MET expression and methods of focusing on MET remedy in superior gastric most cancers. Entrance. Oncol. 11, 719217 (2021).
Ughetto, S. et al. Customized therapeutic methods in HER2-driven gastric most cancers. Gastric Most cancers 24, 897–912 (2021).
Piro, G. et al. An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric most cancers sufferers. Clin. Most cancers Res. 22, 6164–6175 (2016).
Yu, Y., Yu, X., Liu, H., Tune, Q. & Yang, Y. miR-494 inhibits cancer-initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2-positive gastric most cancers. Int. J. Mol. Med. 42, 998–1007 (2018).
Kim, J. et al. Preexisting oncogenic occasions affect trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J. Clin. Make investments. 124, 5145–5158 (2014).
Jin, M. H. et al. WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers. Gastric Most cancers 24, 1003–1020 (2021).
Oh, Okay. S. et al. An artificial deadly technique utilizing PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers. Oncogene 41, 3939–3952 (2022).
DiPeri, T. P. et al. Adavosertib enhances antitumor exercise of trastuzumab deruxtecan in HER2-expressing cancers. Clin. Most cancers Res. 29, 4385–4398 (2023).
Shi, W. et al. Hyperactivation of HER2–SHCBP1–PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric most cancers. Nat. Commun. 12, 2812 (2021).
Kim, H. P. et al. Testican-1-mediated epithelial–mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric most cancers. Oncogene 33, 3334–3341 (2014).
Zhou, X. et al. miR-200c inhibits TGF-beta-induced-EMT to revive trastuzumab sensitivity by focusing on ZEB1 and ZEB2 in gastric most cancers. Most cancers Gene Ther. 25, 68–76 (2018).
Shi, J. et al. The HER4–YAP1 axis promotes trastuzumab resistance in HER2-positive gastric most cancers by inducing epithelial and mesenchymal transition. Oncogene 37, 3022–3038 (2018).
Ebbing, E. A. et al. Esophageal adenocarcinoma cells and xenograft tumors uncovered to Erb-b2 receptor tyrosine kinase 2 and three inhibitors activate reworking progress issue beta signaling, which induces epithelial to mesenchymal transition. Gastroenterology 153, 63–76 (2017).
Nam, A. R. et al. Focusing on the hippo transducer YAP overcomes trastuzumab-resistance in HER2-positive cancers. Most cancers Res. 2022, 5334 (2022).
Liu, W., Yuan, J., Liu, Z., Zhang, J. & Chang, J. Label-free quantitative proteomics mixed with organic validation reveals activation of Wnt/beta-catenin pathway contributing to trastuzumab resistance in gastric most cancers. Int. J. Mol. Sci. https://doi.org/10.3390/ijms19071981 (2018).
Danzi, F. et al. To metabolomics and past: a technological portfolio to research most cancers metabolism. Sign. Transduct. Goal Ther. 8, 137 (2023).
Hu, X. et al. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric most cancers. Most cancers Commun. 43, 909–937 (2023).
Castagnoli, L. et al. Fatty acid synthase as a brand new therapeutic goal for HER2-positive gastric most cancers. Cell Oncol. 46, 661–676 (2023).
Suh, Okay. J. et al. EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines launch. Oncotarget 8, 63901–63910 (2017).
Fukai, S. et al. Down-regulation of stimulator of interferon genes (STING) expression and CD8(+) T-cell infiltration relying on HER2 heterogeneity in HER2-positive gastric most cancers. Gastric Most cancers 26, 878–890 (2023).
Yuan, Q. et al. Integration of transcriptomics, proteomics, and metabolomics knowledge to disclose HER2-associated metabolic heterogeneity in gastric most cancers with response to immunotherapy and neoadjuvant chemotherapy. Entrance. Immunol. 13, 951137 (2022).
Janjigian, Y. Y. et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the part 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 402, 2197–2208 (2023).
MERCK. Merck Declares Part 3 KEYNOTE-811 Trial Met Twin Main Endpoint of Total Survival (OS) as First-Line Therapy in Sufferers With HER2-Optimistic Superior Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. https://www.merck.com/information/merck-announces-phase-3-keynote-811-trial-met-dual-primary-endpoint-of-overall-survival-os-as-first-line-treatment-in-patients-with-her2-positive-advanced-gastric-or-gastroesophageal-junction-gej/ (2024).
FDA. FDA Amends Pembrolizumab’s Gastric Most cancers Indication. https://www.fda.gov/medicine/resources-information-approved-drugs/fda-amends-pembrolizumabs-gastric-cancer-indication (2023).
Lee, Okay. W. et al. Zanidatamab (zani), a HER2-targeted bispecific antibody, together with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) remedy for sufferers (pts) with superior HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): preliminary outcomes from a part 1b/2 research. J. Clin. Oncol. https://doi.org/10.1200/JCO.2022.40.16_suppl.4032 (2023).
Tabernero, J. et al. HERIZON-GEA-01: zanidatamab + chemo ± tislelizumab for 1L remedy of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 18, 3255–3266 (2022).
Candas-Inexperienced, D. et al. Twin blockade of CD47 and HER2 eliminates radioresistant breast most cancers cells. Nat. Commun. 11, 4591 (2020).
Kauder, S. E. et al. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a positive security profile. PLoS ONE 13, e0201832 (2018).
ALX Oncology. ALX Oncology stories constructive interim part 2 ASPEN-06 scientific trial outcomes of evorpacept for the remedy of superior HER2-positive gastric most cancers. ALX Oncology, https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-reports-positive-interim-phase-2-aspen-06-clinical/ (2023).
Xia, L. et al. HER2-targeted antibody–drug conjugate induces host immunity towards most cancers stem cells. Cell Chem. Biol. 28, 610–624.e5 (2021).
Wu, X. et al. A HER2-targeting antibody–MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon most cancers by triggering the cGAS–STING pathway. Cell. Dying Dis. 14, 550 (2023).
Yadav, G. et al. Synergistic exercise of neratinib together with olaparib in uterine serous carcinoma overexpressing HER2/neu. Gynecol. Oncol. 166, 351–357 (2022).
Wainberg, Z. A. et al. Bemarituzumab in sufferers with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, part 2 research. Lancet Oncol. 23, 1430–1440 (2022).
Yasui, H. et al. Potential evaluation of the expression standing of FGFR2 and HER2 in colorectal and gastric most cancers populations: DS-Display screen Examine. Int. J. Colorectal Dis. 37, 1393–1402 (2022).
Krzyscik, M. A., Porebska, N., Opalinski, L. & Otlewski, J. Focusing on HER2 and FGFR-positive most cancers cells with a bispecific cytotoxic conjugate combining anti-HER2 Affibody and FGF2. Int. J. Biol. Macromol. 254, 127657 (2024).
Fukuoka, S. et al. p70S6K/Akt twin inhibitor DIACC3010 is efficacious in preclinical fashions of gastric most cancers alone and together with trastuzumab. Sci. Rep. 13, 16017 (2023).
Egebjerg, Okay. et al. HER2 positivity in histological subtypes of salivary gland carcinoma: a scientific evaluation and meta-analysis. Entrance. Oncol. 11, 693394 (2011).
Hiraoka, N. et al. Particulars of human epidermal progress issue receptor 2 standing in 454 circumstances of biliary tract most cancers. Hum. Pathol. 105, 9–19 (2020).
Nasioudis, D. et al. Molecular panorama of ERBB2/HER2 gene amplification amongst sufferers with gynecologic malignancies; scientific implications and future instructions. Gynecol. Oncol. 180, 1–5 (2024).
Hirsch, F. R. et al. Analysis of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Most cancers 86, 1449–1456 (2002).
Van Cutsem, E. et al. HER2 screening knowledge from ToGA: focusing on HER2 in gastric and gastroesophageal junction most cancers. Gastric Most cancers 18, 476–484 (2015).
Han, S. H., Ryu, Okay. H. & Kwon, A. Y. The prognostic affect of HER2 genetic and protein expression in pancreatic carcinoma-HER2 protein and gene in pancreatic most cancers. Diagnostics 11, 653 (2021).
Search engine optimization, A. N. et al. HER2 standing in colorectal most cancers: its scientific significance and the connection between HER2 gene amplification and expression. PLoS ONE 9, e98528 (2014).
Scherrer, E., Kang, A., Bloudek, L. M. & Koshkin, V. S. HER2 expression in urothelial carcinoma, a scientific literature evaluation. Entrance. Oncol. 12, 1011885 (2022).
Estephan, F. et al. The prevalence and scientific significance of HER2 expression in prostate adenocarcinoma. Ann. Diagn. Pathol. 67, 152219 (2023).
Shayeb, A. M. et al. Complete evaluation of human epidermal progress issue receptor 2 by way of DNA, mRNA, and protein in numerous malignancies. JCO Summary. Oncol. 7, e2200604 (2023).
Mishra, R., Hanker, A. B. & Garrett, J. T. Genomic alterations of ERBB receptors in most cancers: scientific implications. Oncotarget 8, 114371–114392 (2017).
